Asmaa Reda
Banha University
8 Papers
4 Citations
Asmaa Reda is an academic researcher from Banha University. The author has contributed to research in topics: Cancer & Cellular differentiation. The author has an hindex of 4, co-authored 8 publications.
Chat about Author
Papers
TRAIL combinations: The new ‘trail’ for cancer therapy (Review)
TL;DR: The review suggests specific pathways to be targeted together with TRAIL for more efficient treatment, including cellular FLICE inhibitory protein and its downstream survival factors, the Bcl-2 family and other prominent targets.
82
Superparamagnetic Iron Oxide Nanoparticles (SPIONs) as Multifunctional Cancer Theranostics
Ibrahim M. El-Sherbiny,Mousa El-Sayed,Asmaa Reda +2 more
- 01 Jan 2020
TL;DR: This book chapter will highlight the state-of-the-art designed SPIONs, their fabrication, characterization, and the mechanism of their action in targeting cancer cells, envisaging SPION as a golden therapeutic era tool.
7
Effect of Plasma Activated Mist on Breast Cancer Cells
Mohamed El Shaer,Ahmed Zaki,Asmaa Reda,Mohamed Adel,Mona Mobasher,Sameh S. Ali +5 more
- 01 Mar 2018
TL;DR: In this paper, the effect of PAMI is compared to direct plasma exposure during treatment of breast cancer cells MCF-7 using an ultrasonic nebulizer, where the direct plasma jet is operated with argon gas while the PAMI discharge through ambient air and flowing mist.
4
Role of mitochondria in rescuing glycolytically inhibited subpopulation of triple negative but not hormone-responsive breast cancer cells.
Asmaa Reda,Alaa Refaat,Alaa Refaat,Ahmed A. Abd-Rabou,Ali M. Mahmoud,Mohamed Adel,Salwa Sabet,Sameh S. Ali +7 more
TL;DR: It is confirmed that relative to ER-positive cells (MCF7), TNBC cells (MBA-MD-231) rely more on glycolysis thus providing a rationale to target these cells with Glycolytic inhibitors, and suggested that combined treatment with PARP and mitochondrial inhibitors may provide novel therapeutic strategy against TNBC.
From Human Mesenchymal Stem Cells to Insulin-Producing Cells: Comparison between Bone Marrow- and Adipose Tissue-Derived Cells
Mahmoud M. Gabr,Mahmoud M. Zakaria,Ayman F. Refaie,Engy A. Abdel-Rahman,Asmaa Reda,Sameh S. Ali,Sherry M. Khater,Sylvia A. Ashamallah,Amani M. Ismail,Hossam El-Din Ali Ismail,Nagwa El-Badri,Mohamed A. Ghoneim +11 more
TL;DR: Human bone marrow-derived mesenchymal stem cells and AT-MSCs are comparable regarding their differential potential to form IPCs and the availability and properties of AT- MSCs render them well-suited for applications in regenerative medicine.